BMEA logo

BIOMEA FUSION INC

BMEANASDAQ
🏆 #4137 by market capUS Equity
$182.72▲ $7.67 (+4.20%)
Simulated price
🔔
Track BMEA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.2%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$92M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
56
Weak
No chart data available for BMEA.

Trading Snapshot

Day Range
$181.72 – $184.36
52-Week Range
$0.87 – $2.99
Volume
$3.81B
Avg Volume
$2.84B
Shares Outstanding
72.3M
Next Earnings
Nov 20, 2026

Fundamentals Snapshot

Annual Revenue
$11M
Last Q Revenue
$3M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-0.50
Dividend Yield
—
Dilution (1yr)
+99.4%

Why Investors Own BMEA

  • ✓High-growth profile — revenue up +22.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 74% gross margin and 25% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BMEA logo

BIOMEA FUSION INC

BMEA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$81M▼ −43.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$70M▼ −41.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
72.3M▲ +99.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$54M▲ +$5M YoY
StockOtter · stockotter.space

About BIOMEA FUSION INC

Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$192.57
▲ +5.4% Upside
High Target$232.81
Low Target$157.80
Based on 22 analysts

Latest News & Updates

🚀
Barron’s·2h ago

BIOMEA FUSION INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift BMEA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

BIOMEA FUSION INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.